Price Alert

Vanda Pharmaceuticals Inc... (VNDA)

NASDAQ: VNDA · Real-Time Price · USD

4.41

-0.02 (-0.45%)

At close: Aug 15, 2025, 11:40 AM

Vanda Pharmaceuticals Statistics

Share Statistics

Vanda Pharmaceuticals has 59.09M shares outstanding. The number of shares has increased by 1.11% in one year.

Shares Outstanding	59.09M
Shares Change (YoY)	1.11%
Shares Change (QoQ)	1.06%
Owned by Institutions (%)	75.05%
Shares Floating	55.03M
Failed to Deliver (FTD) Shares	4,977
FTD / Avg. Volume	1.05%

Short Selling Information

The latest short interest is 4.59M, so 7.8% of the outstanding shares have been sold short.

Short Interest	4.59M
Short % of Shares Out	7.8%
Short % of Float	8.09%
Short Ratio (days to cover)	9.5

Valuation Ratios

The PE ratio is -14.74 and the forward PE ratio is -4.24. Vanda Pharmaceuticals's PEG ratio is 0.02.

PE Ratio	-14.74
Forward PE	-4.24
PS Ratio	1.4
Forward PS	0.8
PB Ratio	0.52
P/FCF Ratio	-17.14
PEG Ratio	0.02

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Vanda Pharmaceuticals.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.39, with a Debt / Equity ratio of 0.02.

Current Ratio	4.39
Quick Ratio	4.37
Debt / Equity	0.02
Debt / EBITDA	-0.38
Debt / FCF	-0.76
Interest Coverage	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$540.14K
Profits Per Employee	$-51.36K
Employee Count	368
Asset Turnover	0.3
Inventory Turnover	6.56

Taxes

Income Tax	-4.02M
Effective Tax Rate	17.54%

Stock Price Statistics

The stock price has increased by -18.52% in the last 52 weeks. The beta is 0.72, so Vanda Pharmaceuticals's price volatility has been higher than the market average.

Beta	0.72
52-Week Price Change	-18.52%
50-Day Moving Average	4.61
200-Day Moving Average	4.62
Relative Strength Index (RSI)	34.24
Average Volume (20 Days)	475,491

Income Statement

In the last 12 months, Vanda Pharmaceuticals had revenue of 198.77M and earned -18.9M in profits. Earnings per share was -0.33.

Revenue	198.77M
Gross Profit	187.46M
Operating Income	-40.66M
Net Income	-18.9M
EBITDA	-32.53M
EBIT	-40.66M
Earnings Per Share (EPS)	-0.33

Full Income Statement

Balance Sheet

The company has 102.32M in cash and 12.36M in debt, giving a net cash position of 89.96M.

Cash & Cash Equivalents	102.32M
Total Debt	12.36M
Net Cash	89.96M
Retained Earnings	-174.29M
Total Assets	624.75M
Working Capital	273.43M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -15.76M and capital expenditures -490K, giving a free cash flow of -16.25M.

Operating Cash Flow	-15.76M
Capital Expenditures	-490K
Free Cash Flow	-16.25M
FCF Per Share	-0.28

Full Cash Flow Statement

Margins

Gross margin is 94.31%, with operating and profit margins of -20.46% and -9.51%.

Gross Margin	94.31%
Operating Margin	-20.46%
Pretax Margin	-11.53%
Profit Margin	-9.51%
EBITDA Margin	-16.36%
EBIT Margin	-20.46%
FCF Margin	-8.17%

Dividends & Yields

VNDA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for VNDA is $20, which is 378.5% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$20
Price Target Difference	378.5%
Analyst Consensus	Strong Buy
Analyst Count	3

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	0.94
Piotroski F-Score	3